CRMD: CorMedix Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 225.97
Enterprise Value ($M) 182.33
Book Value ($M) 70.14
Book Value / Share 1.28
Price / Book 3.22
NCAV ($M) 67.53
NCAV / Share 1.23
Price / NCAV 3.35

Profitability (mra)
Return on Invested Capital (ROIC) -0.65
Return on Assets (ROA) -0.75
Return on Equity (ROE) -0.84

Liquidity (mrq)
Quick Ratio 6.78
Current Ratio 6.97

Balance Sheet (mrq) ($M)
Current Assets 79.45
Assets 82.06
Liabilities 11.92
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -48.96
Net Income -46.34
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -38.41
Cash from Investing -17.06
Cash from Financing 55.92

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Nomura Holdings Inc 5.40 -0.20
02-13 13G Vanguard Group Inc 5.15
01-29 13G BlackRock Inc. 6.40 449.99

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIO
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P
2023-03-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTIO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-27 106,527 331,516 32.13
2024-03-26 96,996 455,547 21.29
2024-03-25 59,503 489,686 12.15
2024-03-22 86,268 381,421 22.62

(click for more detail)

Similar Companies
CHRS – Coherus BioSciences, Inc. CLSD – Clearside Biomedical, Inc.
CMRX – Chimerix, Inc. CRON – Cronos Group Inc.
CRSP – CRISPR Therapeutics AG


Financial data and stock pages provided by
Fintel.io


Finpedia: CorMedix